Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. The team has demonstrated the success of the approach as Eve discovered that a compound shown to have anti-cancer properties might also be used in the fight against malaria.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
The University of Cambridge has received £7.9 million from the National Institute for Health Research (NIHR) to fund Blood and Transplant Research Units. Each Unit is a partnership between University researchers and NHS Blood and Transplant, and will begin in October 2015.
A trawl through a library of more than 50,000 ‘small molecules’ has identified a potential candidate to inhibit the spread of cancer cells throughout the body. Reported today in the journal Nature Communications, the molecule targets a mechanism of tumour development that had previously been considered ‘undruggable’– in other words, extremely difficult, if not impossible, to target with a drug – and could open the door to further promising new candidates.
DefiniGEN is one of the first commercial opportunities to arise from Cambridge’s expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic cells for drug screening.
An experimental drug currently being trialled for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus. A team of researchers at the University of Cambridge has shown that the drug, favipiravir, is effective at reducing – and in some cases eliminating – norovirus infection in mice.
Launched today (26 September), Cancer Core Europe brings together six cancer centres – including the Cambridge Cancer Centre at the University of Cambridge – to link cancer research through to cancer care.
A daily supplement of an extract found in tomatoes may improve the function of blood vessels in patients with cardiovascular disease, according to new research from the University of Cambridge.
Miniature scaffolds made from collagen – the ‘glue’ that holds our bodies together – are being used to heal damaged joints, and could be used to develop new cancer therapies or help repair the heart after a heart attack.
Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
© 2025 University of Cambridge